Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Why do we celebrate the International Clinical Trials Day?

What happened 271 ago? In May 1747, at a time when scurvy was rampant among sailors, James Lind, a pioneer of naval hygiene, conducted what is now considered to be the very first clinical trial. Lind, a surgeon mate on board HMS Salisbury, recruited twelve men into a study that investigated which acidic substances could cure scurvy (spoiler alert: it was citrus fruits).

Clinical Trials DaySince then, May 20th is widely celebrated as the International Clinical Trials Day. It is an occasion to highlight the importance of clinical trials, raise awareness of participation opportunities and discuss the process of volunteering – and members of Paediatrics’ Oxford Vaccine Group have been on board with the celebrations. Alongside leaflets and stickers, Annabel Coxon and Rebecca Beckley brought in a set of Lego people, which helped to explain how herd immunity works. The Lego game has been a hit with children and adults alike!

To get involved in the clinical trials run by Paediatrics, visit our recruiting page.

 

 

 

 

 

 

 

 

 

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.